In this prospective study, microdrops (mean drop volume 5.6 microl) and commercially available standard drops (mean drop volume 35.4 microl) of cyclopentolate, phenylephrine and tropicamide's clinical efficacy and systemic side effects were compared. Sixty-one infants requiring diagnostic pupil dilatation were studied for pupillary diameter, systemic blood pressure, heart rate and skin flushing changes related to the instillation of mydriatic drops. Both microdrops and standard drops of the drugs produced significant increase in pupillary diameter compared with the baseline (p<0.01). In cyclopentolate and phenylephrine groups, there was no significant pupillary diameter changes between microdrops and standard drops (p>0.05). Mean blood pressure increased significantly in infants given standard drops. There was no significant change in the group that was given microdrops. In our opinion, reduced volume of mydriatics can prevent possible side effects.

Abstract:The importance of an automobile's headlamps in the dark is inferable from the results of studies. Various regulations are available in order to arrange the required illuminance values at certain positions on the road. The designed and produced headlamps have to satisfy the requirements of these regulations. Manual measurement tools, such as the luxmeter (which are based on point-by-point measurements), have traditionally been used. This traditional way has been considered inefficient in terms of awkward setup procedures, complexity, the continuous intervention of human operators, and costs. In this study, in order to overcome these problems, a new approach for measuring the illuminance values is proposed. Combining a digital still camera with a fuzzy mapping algorithm, a fast and economic tool to measure the illuminance values of the entire measuring screen is developed. The proposed method was tested on two different brands of headlamps and its effectiveness has been proved.

A placebo-controlled, prospective study was undertaken to determine whether apraclonidine has an additive effect in eyes treated with timolol and pilocarpine. Twelve patients with primary open-angle glaucoma while on continuing therapy with timolol 0.5% twice daily and pilocarpine 4% four times a day in both eyes for 3 months were included in the study. A single drop of apraclonidine 1% or placebo was added to treatment with timolol and pilocarpine. Intraocular pressure (IOP) was measured on both days before a single drop of test medications in both eyes as well as 2,4,6, 8 and 12 h later. The fall in IOP with apraclonidine was significantly greater than with placebo at all time intervals (p < 0.05). This study suggests that apraclonidine provides an additive IOP-lowering effect to timolol and pilocarpine for at least 12 h after single-drop applications.